Tackling smoking cessation systematically among inpatients with heart disease
- PMID: 29581160
- PMCID: PMC5871437
- DOI: 10.1503/cmaj.180125
Tackling smoking cessation systematically among inpatients with heart disease
Conflict of interest statement
Competing interests: Robert Reid has received speaking fees and a research grant from Pfizer, the maker of varenicline, and has received speaking fees from Johnson & Johnson, which manufactures smoking-cessation therapies. Kerri-Anne Mullen has received speaking fees from Pfizer. Andrew Pipe has received funding, and served as a consultant to, Pfizer and Johnson & Johnson. All of the authors are inventors of the Ottawa Model for Smoking Cessation, a registered trademark of the University of Ottawa Heart Institute.
Comment on
-
Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.CMAJ. 2018 Mar 26;190(12):E347-E354. doi: 10.1503/cmaj.170377. CMAJ. 2018. PMID: 29581161 Free PMC article. Clinical Trial.
References
-
- Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J 2013;34:3259–67. - PubMed
-
- Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52. - PubMed
-
- Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical